/* */ PELVIPHARM - L-NAME induced hypertension in rats - mice
Receive our news

 

L-NAME induced hypertension in rats - mice

Model advantages

This experimental model easily creates generalized nitric oxide (NO) deficiency that if prolonged, is responsible for a progressive increase in arterial pressure associated cardiovascular remodeling.

Pathophysiological features

Cardiovascular features :

  • progressive increase of mean arterial pressure
  • cardiac and vascular remodeling if treatment period is sufficiently prolonged

Erectile function features :

  • Dramatic impairment of erectile responses to electrical stimulation of the cavernous nerve after 4 weeks of L-NAME administration (10 or 50 mg/kg/d in drinking water) in anesthetized rats (figure 1).
  • Dose dependent decrease erectile responses to electrical stimulation of the cavernous nerve following acute L-NAME intravenous injection (1 or 3 mg/kg) in anesthetized rats (figure 1).
Figure 1: Effects of acute L-NAME (1 or 3 mg/kg i.v.) and chronic L-NAME (10 or 50 mg/kg/d p.o. for 4 weeks) on intracavernosal pressure (ICP) after ES CN in anesthetized rats (Pelvipharm internal data).
Figure 1: Effects of acute L-NAME (1 or 3 mg/kg i.v.) and chronic L-NAME (10 or 50 mg/kg/d p.o. for 4 weeks) on intracavernosal pressure (ICP) after ES CN in anesthetized rats (Pelvipharm internal data).

Pathophysiological

  • Chronic L-NAME is administered orally in drinking water
  • Acute L-NAME is administered intravenously at the time of experiment
Related Pelvipharm bibliography
Non disclosable information for confidentiality reasons
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL